Navigation Links
Phase 1 / 2 Clinical Trial Results of KRX-0401 (Perifosine) Plus Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma Published in the Journal of Clinical Oncology
Date:10/13/2011

rectal cancer and multiple myeloma, and in Phase 1 and 2 clinical development for several other tumor types. Each of the KRX-0401 Phase 3 studies is being conducted under a Special Protocol Assessment (SPA) agreement with the FDA. Keryx is also developing Zerenex (ferric citrate), an oral, ferric iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. The Phase 3 clinical program of Zerenex for the treatment of hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease is being conducted pursuant to an SPA agreement with the FDA.  Keryx is headquartered in New York City.

Cautionary Statement

Some of the statements included in this press release, particularly those anticipating future clinical trials and business prospects for KRX-0401 (perifosine), may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Among the factors that could cause our actual results to differ materially are the following: our ability to successfully and cost-effectively complete clinical trials for KRX-0401 (perifosine); the risk that the data (both safety and efficacy) from the ongoing Phase 3 clinical trials will not coincide with the data analyses from prior pre-clinical and clinical trials previously reported by the Company, or will not meet the key efficacy and safety parameters specified in the Special Protocol Assessments; and other risk factors identified from time to time in our reports filed with the Securities and Exchange Commission. Any forward-looking statements set forth in this press release speak only as of the date of this press release. We do not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. This press release and pri
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Telik Announces Initiation of a Phase 2b Clinical Trial of Telintra® (Ezatiostat HCL) in Patients With Low to Intermediate-1 Risk Non-Deletion (5q) Myelodysplastic Syndrome
2. Merrimack Pharmaceuticals Initiates Enrollment in a Neoadjuvant Phase 2 Study of MM-121 with Paclitaxel in HER2-negative Breast Cancer Patients
3. Omeros Announces First Patients Treated in Phase 3 Clinical Program Evaluating OMS302
4. Hepatitis C Phase 2A Trial Positive Results
5. Daval International Announces Positive Phase II Results for AIMSPRO® as a Monotherapy in Established Diffuse Cutaneous Systemic Sclerosis (Scleroderma)
6. Journal of Clinical Oncology Publishes Phase 2 Clinical Trial Results of KRX-0401 (Perifosine) Plus Capecitabine in Patients with Metastatic Colorectal Cancer
7. GeoVax Phase 2a Clinical Trial Completes Enrollment
8. Telik Announces Publication in the Journal Cancer of a Phase 2 Randomized Multicenter Study of Two Extended Dosing Schedules of Oral Ezatiostat in Low to Intermediate-1 Risk Myelodysplastic Syndrome
9. Vitala™ Pouchless Continence Control Device Shown to be Safe and Effective for up to 12 Hours in Phase 3 Clinical Trial
10. Visual Healthcare to Supply Enabling Technology for Home Care Consortium Software and Support Revenues to Reach $17 M in Phase One
11. Adamas Pharmaceuticals Initiates a Phase 2/3 Clinical Study of ADS-5102 for Parkinsons Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2014)... -- An International Trade Commission (ITC) ruling issued Friday held ... Taiwanese device manufacturer APEX continues to infringe ResMed patents ... is the innovation leader and pioneer in designing and ... "Our research and development teams are constantly ... comfort, performance and efficacy," said David Pendarvis , ...
(Date:7/21/2014)... July 21, 2014 Apex Medical Corporation (Apex, ... and Pressure Area Care sectors, announces that the United ... advisory opinion, determining that Apex,s newly designed XT series ... 220 mask are free from the patent claims asserted ... declares its plan of introducing an upgraded iCH water ...
(Date:7/18/2014)... Hanger, Inc. (NYSE: HGR ) announced today that ... quarter ended June 30, 2014, on Tuesday, August 5, 2014 ... results is scheduled to begin at 9:00 a.m., ET, on ... 1-877-662-6095. A replay will be available until Thursday, August 14, ... About Hanger, Inc. – Built on the legacy ...
Breaking Medicine Technology:ITC Rules Redesigned APEX Humidifier Still Infringes ResMed Patents 2Apex Medical's Respiratory Therapy Product Receives Affirmation from USITC 2
(Date:7/22/2014)... 22, 2014 A new and technologically ... laxity with results that are surprising even the most ... the skin with radio frequency, ThermiTight has been dubbed ... under the skin to “inject” heat to the tissues ... this single treatment solution for skin laxity produces results ...
(Date:7/21/2014)... to target and kill cancer cells could boost the ... help avoid amputation, a new study reports. , Scientists ... effectiveness of a genetically engineered version of the virus ... of the virus alongside isolated limb perfusion chemotherapy ... or leg as an alternative to amputation was ...
(Date:7/21/2014)... (PRWEB) July 22, 2014 Recently, Stwd.co.uk, a ... of cheap wedding dresses. Additionally, the company’s chief executive officer ... at discounted prices, up to 58% off. , “All our ... The special offer is launched to bring huge benefits to ... collection of cheap wedding outfits. By the way, we offer ...
(Date:7/21/2014)... USA (PRWEB) July 21, 2014 As ... Rappel Down Westin Hotel to Raise Addiction Awareness (7/15), ... by rappelling down a 27-story building in Downtown Philly. ... in the event at the Westin Convention Center Hotel. ... loved one's addiction. One man participated because his son ...
(Date:7/21/2014)... July 21, 2014 What do romance, ... have in common? You can find them all in ... novel's main character, Miranda, lives on Martha’s Vineyard with ... a wealthy New Yorker, and becomes entangled in a ... Heart challenges readers to think about what choices they ...
Breaking Medicine News(10 mins):Health News:New Minimally Invasive Procedure, ThermiTight, “Injects” Radio Frequency to Treat Skin Laxity 2Health News:Viral therapy could boost limb-saving cancer treatment 2Health News:Viral therapy could boost limb-saving cancer treatment 3Health News:2014 Cheap Wedding Dresses, Newest Items Offered by Professional Company Stwd.co.uk 2Health News:100 People Climb Down Building to Raise Drug Addiction Awareness in Philadelphia 2Health News:100 People Climb Down Building to Raise Drug Addiction Awareness in Philadelphia 3Health News:Thea Marsh Releases Debut Novel that Celebrates and Reaches out to Women Everywhere 2
... LAFAYETTE, Ind. - A nanoparticle growing in popularity as a ... according to a Purdue University study. Tested on fathead ... of toxicity on aquatic life -- nanosilver suspended in solution ... nanosilver was allowed to settle, the solution became several times ...
... ... healthy living and health care, there is a greater demand for online resources which provides ... and about health care. New Website, MeTheDoctor.com, gives readers resources they need to take charge ... ...
... ... and CEO of Novasys Medical Inc., will receive the Adaptive Business Leaders Organization (ABL)’s ... Innovations in HealthcareSM Awards Event, on April 28, in Newport Beach, California. , ... Santa Ana, CA (PRWEB) ...
... ... ... ... ...
... , ... ... ... ...
... March 2010 - Think back to your last fight with someone ... you behave? Conflict with a loved one often leaves a person ... these scenarios have become soap opera clichs. After an argument, ... a local bar to drown their sorrows in alcohol. These ...
Cached Medicine News:Health News:Popular nanoparticle causes toxicity in fish, study shows 2Health News:MeTheDoctor.com Helps Consumers Make Informed Decisions About Their Health 2Health News:Novasys Medical's Debra Reisenthel Named ABL's 2010 “Leadership in Innovation” Awardee 2Health News:Novasys Medical's Debra Reisenthel Named ABL's 2010 “Leadership in Innovation” Awardee 3Health News:National Hispanic Council on Aging Joins the Administration in Mission to Combat Medicare Fraud By Empowering Hispanics 2Health News:National Hispanic Council on Aging Joins the Administration in Mission to Combat Medicare Fraud By Empowering Hispanics 3Health News:National Hispanic Council on Aging Joins the Administration in Mission to Combat Medicare Fraud By Empowering Hispanics 4Health News:National Hispanic Council on Aging Joins the Administration in Mission to Combat Medicare Fraud By Empowering Hispanics 5Health News:AMA Honors California County Supervisor With Top Government Service Award 2Health News:AMA Honors California County Supervisor With Top Government Service Award 3Health News:Don't make that face at me! 2
... The SJM Tailor Flexible Band ... a convenient and time-saving alternative for ... It complements the SJM Tailor® Annuloplasty ... who usually implant full rings, but ...
This CLS number is a new product number, created to easily match Cornings product number. If showing no availability yet, please order under the old Sigma-Aldrich number (Z71,407-0) or contact custom...
Pipetman P is a fully adjustable, air-displacement pipette with the selected volume shown on a digital indicator (volumeter). Eight models cover the full range of volumes from 0.2 L to 10 mL....
... The AlphaPette Pipettor is the #1 ... Offers accuracy, comfort, and reliability. Continuously ... volume readout sub-micrometer. Easy interchangeable ejector ... tiny hands. Adjustable rapid pipet tip ...
Medicine Products: